Document is current
Any future updates will be listed below
-
Authors
Fröling, Emma https://orcid.org/0009-0000-6501-3361
Morales Sahm, Mariel https://orcid.org/0009-0005-8880-0380
Schmude, Marcel https://orcid.org/0000-0002-7519-1724
Assies, Charlotte P.
Wittenberg, Michael https://orcid.org/0000-0003-4526-1856
Rosenow, Felix https://orcid.org/0000-0002-3989-7471
Bermpohl, Felix https://orcid.org/0000-0002-3260-6328
Riemer, Thomas G. https://orcid.org/0000-0002-8068-3192
- License Information
-
More Information
Article History
Received: 23 December 2025
Revised: 27 February 2026
Accepted: 28 February 2026
First Online: 13 March 2026
Declarations
:
: FR has received honoraria for lecturing and consultation from Angelini Pharma, Eisai GmbH, Jazz Pharma, Roche Pharma, Stoke Therapeutics, Takeda, and UCB Pharma, and has received financial research support from Dr. Schär Deutschland GmbH, Vitaflo Deutschland GmbH, Nutricia Milupa GmbH, Desitin Pharma, Hamburg, Federal State of Hessen (via the LOEWE-Programme), Chaja Foundation Frankfurt, Reiss Foundation Frankfurt, Dr. Senckenbergische Foundation Frankfurt, Ernst Max von Grunelius Foundation Frankfurt, and Detlev-Wrobel Fonds for Epilepsy Research Frankfurt, outside the submitted work. The remaining authors declare that they have no conflict of interest. EF and MMS are employees of Pfizer Pharma GmbH. This research was conducted independently and was not influenced by their employment. The authors have no relevant financial or non-financial interests to disclose.
: Registered in PROSPERO: CRD42023491050 (6.12.2023) and CRD420251003207 (3.3.2025).
